First AD

Second AD

FLAURA and FLAURA2: Key Efficacy and Safety Data

Video content above is prompted by the following:

Please comment on the PFS and OS data for osimertinib monotherapy vs combination therapies in FLAURA and FLAURA2.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Unraveling The Key Questions in EGFR-Driven NSCLC Treatment 

OncLive Insights

Panelists discuss how osimertinib monotherapy demonstrated robust progression-free survival and overall survival benefits in FLAURA, while FLAURA2 showed that adding chemotherapy to osimertinib further improved progression-free survival (PFS) although overall survival (OS) data remains immature, leading to ongoing debate about the optimal first-line approach.